Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Latest, Q2 2026
12,564
Period ended Jun 30, 2026
Change on a year earlier
+6.1%
11,846 in Q2 2025
History
68 quarters
Since Q4 2008
Sources
66
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accounts Receivable, Net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 12,564 | +6.1% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 12,210 | +13.2% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 11,775 | +14.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 12,120 | +6.5% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 11,846 | +1.8% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 10,790 | -5.1% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 10,278 | -0.7% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 11,381 | +9.5% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 11,642 | +5.5% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 11,366 | +9.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 10,349 | +9.5% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 10,394 | +9.6% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 11,030 | +14.4% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 10,415 | +6.0% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 9,450 | +2.4% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2022 | Sep 30, 2022 | 9,482 | +10.6% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 9,643 | +23.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 9,828 | +19.3% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 9,230 | +35.7% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 8,571 | +1.8% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 7,843 | +3.5% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 8,235 | +0.6% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 6,803 | +0.4% | Form 10-Q (filed 2021-08-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 8,422 | -0.2% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 7,577 | -4.9% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 8,182 | +7.5% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 6,778 | -4.1% | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2019 | Sep 30, 2019 | 8,442 | +14.5% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 7,964 | +9.3% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 7,608 | +5.0% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 7,071 | +2.9% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 7,374 | -3.9% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 7,287 | -2.0% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 7,245 | +2.5% | Form 10-Q (filed 2018-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 6,873 | -2.1% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 7,671 | +4.2% | SEC Filing ↗ |
| Q2 2017 | Jun 30, 2017 | 7,439 | +7.6% | SEC Filing ↗ |
| Q1 2017 | Mar 31, 2017 | 7,066 | +3.2% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 7,018 | +8.2% | SEC Filing ↗ |
| Q3 2016 | Sep 30, 2016 | 7,364 | +14.8% | SEC Filing ↗ |
| Q2 2016 | Jun 30, 2016 | 6,916 | +6.2% | SEC Filing ↗ |
| Q1 2016 | Mar 31, 2016 | 6,850 | +2.7% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 6,484 | -2.1% | Form 10-K (filed 2016-02-26) ↗ |
| Q3 2015 | Sep 30, 2015 | 6,414 | -1.6% | Form 10-Q (filed 2015-11-05) ↗ |
| Q2 2015 | Jun 30, 2015 | 6,510 | -7.3% | Form 10-Q (filed 2015-08-06) ↗ |
| Q1 2015 | Mar 31, 2015 | 6,670 | -7.2% | Form 10-Q (filed 2015-05-07) ↗ |
| Q4 2014 | Dec 31, 2014 | 6,626 | -7.8% | Form 10-K (filed 2015-02-27) ↗ |
| Q3 2014 | Sep 30, 2014 | 6,515 | -14.0% | Form 10-Q (filed 2014-11-10) ↗ |
| Q2 2014 | Jun 30, 2014 | 7,022 | – | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 7,188 | -9.8% | Form 10-Q (filed 2014-05-08) ↗ |
| Q4 2013 | Dec 31, 2013 | 7,184 | -6.4% | Form 10-K (filed 2014-02-27) ↗ |
| Q2 2013 | Sep 30, 2013 | 7,578 | -4.7% | Form 10-Q (filed 2013-11-07) ↗ |
| Q1 2013 | Mar 31, 2013 | 7,965 | -8.7% | Form 10-Q (filed 2013-05-09) ↗ |
| Q4 2012 | Dec 31, 2012 | 7,672 | -7.1% | Form 10-K (filed 2013-02-28) ↗ |
| Q3 2012 | Sep 30, 2012 | 7,952 | -2.3% | Form 10-Q (filed 2012-11-09) ↗ |
| Q2 2012 | Jun 30, 2012 | 8,152 | -3.8% | Form 10-Q (filed 2012-08-07) ↗ |
| Q1 2012 | Mar 31, 2012 | 8,726 | – | Form 10-Q (filed 2012-05-08) ↗ |
| Q4 2011 | Dec 31, 2011 | 8,261 | +12.5% | Form 10-K (filed 2012-02-28) ↗ |
| Q3 2011 | Sep 30, 2011 | 8,136 | +11.5% | Form 10-Q (filed 2011-11-08) ↗ |
| Q2 2011 | Jun 30, 2011 | 8,475 | +35.0% | Form 10-Q (filed 2011-08-08) ↗ |
| Q4 2010 | Dec 31, 2010 | 7,344 | +11.2% | Form 10-K (filed 2011-02-28) ↗ |
| Q3 2010 | Sep 30, 2010 | 7,298 | +133.4% | Form 10-Q (filed 2010-11-08) ↗ |
| Q2 2010 | Jun 30, 2010 | 6,276 | +98.4% | Form 10-Q (filed 2010-08-06) ↗ |
| Q1 2010 | Mar 31, 2010 | 7,498 | – | Form 10-Q (filed 2010-05-07) ↗ |
| Q4 2009 | Dec 31, 2009 | 6,603 | +127.1% | Form 10-K (filed 2011-02-28) ↗ |
| Q3 2009 | Sep 30, 2009 | 3,127 | – | Form 10-Q (filed 2009-10-29) ↗ |
| Q2 2009 | Jun 30, 2009 | 3,164 | – | Form 10-Q (filed 2009-07-24) ↗ |
| Q4 2008 | Dec 31, 2008 | 2,908 | – | Form 10-K (filed 2010-03-01) ↗ |
Breakdown
What makes up accounts receivable, net ($m)
Cite this data
StockData. (2026). Merck Accounts Receivable, Net ($M) ($M), quarterly Q4 2008–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_bal_ar
See every metric in the Merck KPI table. Data updated Oct 26, 2026.